Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo

ClinicalTrials.gov ID: NCT00739986

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00739986. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment vs. Placebo

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).

Study identification

NCT ID
NCT00739986
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Ferring Pharmaceuticals
Industry
Enrollment
152 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2002 (Type not available)
Primary completion
Jun 2004 (Actual)
Completion
Aug 2004 (Actual)
Last update posted
Nov 9, 2023

2002 – 2004

United States locations

U.S. sites
10
U.S. states
5
U.S. cities
10
Facility City State ZIP Site status
Institute of Healthcare Assessment San Diego California 92120 —
University of California, San Francisco San Francisco California 94115 —
Atlanta Gastroenterology Associates Atlanta Georgia 30342 —
Advanced Gastroenterology Associates Suwanee Georgia 30024 —
Northwestern University Chicago Illinois 60611 —
Long Island Clinical Research Associates Great Neck New York 11021 —
Asher Kornbluth, MD New York New York 10128 —
Rochester General Hospital Rochester New York 14621 —
Gastroenterology Associates Bristol Tennessee 37620 —
Gastroenterology Associates Kingsport Tennessee 37660 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00739986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 9, 2023 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.